Prestige BioPharma Pte Ltd

Prestige BioPharma Pte Ltd (PBP) is a biopharmaceutical company that develops biosimilars and new antibody therapeutics. Addressing unmet medical needs in the fields of immunology, and degenerative and metabolic disorders, PBP is a leading company in the industry.


Octava is an investor in PBP’s pursuit of drug discovery, and the development and research on oncology and immune disorders.  PBP is based in Singapore and has had successful results in the Phase I clinical trial on its first biosimilar in 2014.